Cardiac Rehab Effects in HFpEF
Primary Purpose
Heart Failure With Preserved Ejection Fraction
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Afferent block
Sponsored by
About this trial
This is an interventional treatment trial for Heart Failure With Preserved Ejection Fraction
Eligibility Criteria
Inclusion Criteria:
- heart failure with preserved ejection fraction
Exclusion Criteria:
- heart failure with reduced ejection fraction
Sites / Locations
- VA Salt Lake City Health Care System, Salt Lake City, UTRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Afferent effect on hemodynamics
Afferent effect on fatigue
Effect of cardiac rehab
Arm Description
Evaluate impact of group III/IV muscle afferents on femoral blood flow
Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
Outcomes
Primary Outcome Measures
femoral blood flow
Quantifying femoral blood flow during exercise with and without afferent blockade
Secondary Outcome Measures
femoral blood flow
Impact of cardiac rehab on the influence of afferent blockade on femoral blood flow
Full Information
NCT ID
NCT04506606
First Posted
August 6, 2020
Last Updated
June 6, 2023
Sponsor
VA Office of Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT04506606
Brief Title
Cardiac Rehab Effects in HFpEF
Official Title
Efficacy of Exercise Training in Patients With HFpEF
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 2, 2022 (Actual)
Primary Completion Date
September 30, 2025 (Anticipated)
Study Completion Date
September 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This research in Veterans with heart failure with preserved ejection fraction (HFpEF) will provide new information on the mechanisms determining the patients' exercise intolerance and the efficacy of regular physical activity to improve this shortcoming by alleviating the patients' neurocirculatory abnormalities. Specifically, the investigators will focus on the role of nerves originating in working limb muscles in determining the patients' exercise intolerance and compromised fatigue resistance before and after a chronic exercise intervention. By focusing on a specific mechanism, this project will evaluate the validity of exercise as an alternative treatment strategy with the overall purpose of improving the quality of life of Veterans with HFpEF.
Detailed Description
Patients with heart failure with preserved ejection fraction (HFpEF) are characterized by exercise intolerance and premature fatigue during physical activity. An abnormal exercise pressor reflex mediated by neural feedback from mechano- and/or metabosensitive group III and IV muscle afferents may contribute to these debilitating symptoms. However, little is known about the role and relative contribution of group III/IV afferents in circulatory control and fatigue development in patients with HFpEF. By studying both patients with HFpEF and well-matched controls, the investigators will evaluate the contribution of these muscle afferents to circulatory control and fatigue development, factors recognized to be major contributors to exercise intolerance. The investigators will use lumbar intrathecal fentanyl to block the central projection of group III/IV muscle afferents during voluntary and passive exercise (no concomitant effect on feedforward drive). This proven approach will enable us to evaluate, and distinguish between, the effects of group III and IV muscle afferents on central and peripheral hemodynamics during exercise, the exercise-induced development of central and peripheral fatigue (femoral nerve stimulation techniques), and on exercise tolerance. The investigators will also study muscle morphometry, baroreflex and chemoreflex sensitivity, and investigate intramuscular metabolic changes of the quadriceps during exercise using 31phosphorus magnetic resonance spectroscopy to evaluate disease-related alterations in cardiovascular reflex sensitivity and intrinsic muscle characteristics as a potential factor determining alterations in circulatory control and fatigue resistance in patients with HFpEF. Finally, the investigators will repeat these studies after a supervised 12-week knee-extension exercise training program, allowing us to investigate the effect of chronic exercise on the role of group III/IV muscle afferents in the hemodynamic response to exercise, the development of fatigue, and, ultimately, exercise tolerance. If this project confirms a significant contribution of group III/IV muscle afferents to the exercise intolerance exhibited by patients with HFpEF, and that chronic exercise can alleviate these impairments, the proposed work will provide the scientific basis for a paradigm shift in the treatment of this growing population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure With Preserved Ejection Fraction
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Afferent effect on hemodynamics
Arm Type
Experimental
Arm Description
Evaluate impact of group III/IV muscle afferents on femoral blood flow
Arm Title
Afferent effect on fatigue
Arm Type
Experimental
Arm Description
Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
Arm Title
Effect of cardiac rehab
Arm Type
Experimental
Arm Description
Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
Intervention Type
Procedure
Intervention Name(s)
Afferent block
Intervention Description
Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
Primary Outcome Measure Information:
Title
femoral blood flow
Description
Quantifying femoral blood flow during exercise with and without afferent blockade
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
femoral blood flow
Description
Impact of cardiac rehab on the influence of afferent blockade on femoral blood flow
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
heart failure with preserved ejection fraction
Exclusion Criteria:
heart failure with reduced ejection fraction
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Misti R Seppi, MBA BS AAS
Phone
(801) 582-1565
Ext
4860
Email
Misti.Seppi@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Tabitha Randall, MS
Phone
(801) 582-1565
Ext
4855
Email
tabitha.randall@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markus Amann, PhD
Organizational Affiliation
VA Salt Lake City Health Care System, Salt Lake City, UT
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Salt Lake City Health Care System, Salt Lake City, UT
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84148-0001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Misti R Seppi, MBA BS AAS
Phone
801-582-1565
Ext
4860
Email
Misti.Seppi@va.gov
First Name & Middle Initial & Last Name & Degree
Tabitha Randall, MS
Phone
(801) 582-1565
Ext
4855
Email
tabitha.randall@va.gov
First Name & Middle Initial & Last Name & Degree
Markus Amann, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Cardiac Rehab Effects in HFpEF
We'll reach out to this number within 24 hrs